Is Boundless Bio, Inc. (BOLD) a Buy, Sell, or Hold?
Boundless Bio, Inc.
NASDAQ:BOLD
$2.46 USD
$0.02 (0.82%)
- Volume
- 306.99K
- Average Volume
- 1.37M
- Market Capitalization
- $55.29M
- P/E Ratio
- -0.98
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.79
- Year Low
- $0.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.87
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Zachary Hornby |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BOLD |
| CUSIP | 10170A100 |
| CIK | 0001782303 |
| Web | https://boundlessbio.com |
| Phone | 858 766 9912 |
| Currency | USD |
| Employees | 28 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.56 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.87 |
| Quick Ratio | 9.87 |
| Cash Ratio | 1.82 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.12 |
| Price / Cash Flow | -1.16 |
| Price / Book | 0.64 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 20 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.6 |
| Trailing P/E Ratio | -0.98 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-58.2M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -53.60% |
| Return on Assets | -39.72% |
Financials Score
| AltmanZ Score | -2.70 |
| Piotroski Score | 1.00 |
| Working Capital | 85.03M |
| Total Assets | 140.97M |
| Ebit | -55.99M |
| Market Cap | 54.84M |
| Total Liabilities | 54.59M |
Poll Results
About Boundless Bio, Inc. (NASDAQ:BOLD) Stock
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular ... segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
2026-07-02 16:07:00
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
2026-06-25 14:00:00
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
2026-06-23 15:00:00
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire
2026-06-23 14:11:00
NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Boundless Bio, Inc. (NASDAQ: BOLD ) related to its merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.
2026-06-23 11:55:00
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages Boundless Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.
2026-06-23 07:30:00
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-08 07:00:00
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. “We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
2026-04-17 16:49:00
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers
Frequently Asked Questions
-
What is the current Boundless Bio, Inc. (BOLD) stock price?
-
Boundless Bio, Inc.(NASDAQ:BOLD) stock price is $2.46 in the last trading session. During the trading session, BOLD stock reached the peak price of $2.79 while $0.961 was the lowest point it dropped to. The percentage change in BOLD stock occurred in the recent session was 0.82% while the dollar amount for the price change in BOLD stock was $0.02.
-
BOLD's industry and sector of operation?
-
The NASDAQ listed BOLD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BOLD?
-
James L. Freddo | Interim Chief Medical Officer
David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer
Meredith Wesley | Chief Human Resources Officer
Amy Berkley | Senior Vice President of Program Team
Jessica Oien | President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary -
How many employees does BOLD have?
-
Number of BOLD employees currently stands at 28. BOLD operates from 9880 Campus Point Drive, San Diego, CA 92121, US.
-
Link for BOLD official website?
-
Official Website of BOLD is: https://boundlessbio.com
-
How do I contact BOLD?
-
BOLD could be contacted at phone #858 766 9912 and can also be accessed through its website. BOLD operates from 9880 Campus Point Drive, San Diego, CA 92121, US.
-
How many shares of BOLD are traded daily?
-
The average number of BOLD shares traded daily for last 3 months was 1.37M.
-
What is the market cap of BOLD currently?
-
The market value of BOLD currently stands at $55.29M with its latest stock price at $2.46